Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials

Journal of Orthopaedic Surgery and Research

Zhijun Pan¹  Shigui Yan¹  Gang Chen¹  Fangcai Li¹  Deting Xue¹ 

[1] Department of Orthopaedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, #88 Jiefang Road, Hangzhou 310009, China

关键词: Meta-analysis;    Randomized controlled trials;    Lumbar fusion;    Indirect bone healing;    Bisphosphonates;   

Others  :  813289
DOI  :  10.1186/1749-799X-9-45

 received in 2014-02-23, accepted in 2014-05-23,  发布年份 2014

【 摘 要 】

Background

Whether bisphosphonates affect indirect bone healing is still unclear.

Method

We carried out a comprehensive search strategy. Only randomized controlled trials were included. Two reviewers independently assessed methodological qualities and extracted outcome data. Analysis was performed with RevMan 5.2.

Results

Eight eligible randomized controlled trials with 2,508 patients were included. Meta-analysis results showed that no statistically significant differences were founded in indirect bone healing in short time (within 3 months) (relative risk (RR) 1.40, relative the control group; 95% CI 0.36 to 5.49) and in long-term (more than 12 months) postoperation (RR 1.0; 95% CI 0.98 to 1.02) between bisphosphonates infusion groups and control groups. There were no statistically significant differences of indirect bone healing between early and delay bisphosphonates administration groups. Bisphosphonates infusion after lumbar infusion surgery could promote bone healing and shorten fusion time in 6 months postoperation (RR 1.35; 95% CI 1.11 to 1.66).

Conclusion

There was no clinically detectable delay to fracture healing via external callus formation following bisphosphonates treatment. Considering the benefit aspects of bisphosphonates for osteoporosis treatment, we recommend bisphosphonates infusion after fracture fixation surgery and lumbar fusion surgery.

【 授权许可】

   
2014 Xue et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Esbrit P, Alcaraz MJ: Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol 2013, 85:1417-1423.
• [2]De Sanctis V, Soliman AT, Elsedfy H, Yassin M, Canatan D, Kilinc Y, Sobti P, Skordis N, Karimi M, Raiola G, Galati MC, Bedair E, Fiscina B, El Kholy M: Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. Pediatr Endocrinol Rev 2013, 11:167-180.
• [3]Kim TY, Ha YC, Kang BJ, Lee YK, Koo KH: Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg Br 2012, 94:956-960.
• [4]Lenehan TM, Balligand M, Nunamaker DM, Wood FE Jr: Effect of EHDP on fracture healing in dogs. J Orthop Res 1985, 3:499-507.
• [5]Adolphson P, Abbaszadegan H, Boden H, Salemyr M, Henriques T: Clodronate increases mineralization of callus after Colles’ fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand 2000, 71:195-200.
• [6]Watkins MP, Norris JY, Grimston SK, Zhang X, Phipps RJ, Ebetino FH, Civitelli R: Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice. Bone 2012, 51:787-794.
• [7]van der Poest CE, Patka P, Vandormael K, Haarman H, Lips P: The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res 2000, 15:586-593.
• [8]Schindeler A, McDonald MM, Bokko P, Little DG: Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol 2008, 19:459-466.
• [9]Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999, 354:1896-1900.
• [10]Bradburn M, Deeks J, Altman D: Sbe24: metan—an alternative meta-analysis command. Stata Technical Bull Reprints 1998, 8:86-100.
• [11]Galbraith RF: A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988, 7:889-894.
• [12]Nagahama K, Kanayama M, Togawa D, Hashimoto T, Minami A: Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial. J Neurosurg Spine 2011, 14:500-507.
• [13]Colón-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C: Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 2011, 22:2329-2336.
• [14]Harding AK AWD, Geijer M, Toksvig-Larsen S, Tagil M: A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies. Acta Orthop 2011, 82:465-470.
• [15]Gong HS, Song CH, Lee YH, Rhee SH, Lee HJ, Baek GH: Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures. J Bone Joint Surg Am 2012, 94:1729-1736.
• [16]Li C, Wang HR, Li XL, Zhou XG, Dong J: The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery. Acta Neurochir (Wien) 2012, 154:731-738.
• [17]Manabe T, Mori S, Mashiba T, Cao Y, Kaji Y, Iwata K, Komatsubara S, Yamamoto T, Seki A, Norimatsu H: Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys. J Bone Miner Metab 2009, 27:295-302.
• [18]Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H: Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002, 17:2237-2246.
• [19]Amanat N, McDonald M, Godfrey C, Bilston L, Little D: Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 2007, 22:867-876.
• [20]Einhorn TA: The cell and molecular biology of fracture healing. Clin Orthop Relat Res 1998, S7-S21.
• [21]Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15:721-739.
• [22]Warriner AH, Saag KG: Osteoporosis diagnosis and medical treatment. Orthop Clin North Am 2013, 44:125-135.
• [23]Orcel P, Funck-Brentano T: Medical management following an osteoporotic fracture. Orthop Traumatol Surg Res 2011, 97:860-869.
• [24]Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P: Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 2009, 24:1308-1313.